{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T08:37:23Z","timestamp":1786523843267,"version":"build-2736575974"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001826","name":"Netherlands Organisation for Health Research and Development","doi-asserted-by":"publisher","award":["10710062310003"],"award-info":[{"award-number":["10710062310003"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eBioMedicine"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.ebiom.2026.106386","type":"journal-article","created":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T21:51:44Z","timestamp":1784238704000},"page":"106386","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Ribavirin post-exposure prophylaxis for Andes virus exposure: a viewpoint"],"prefix":"10.1016","volume":"130","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7618-725X","authenticated-orcid":false,"given":"Roger J.","family":"Br\u00fcggemann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7945-7537","authenticated-orcid":false,"given":"Albert","family":"Vollaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sacha","family":"de Stoppelaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1664-7314","authenticated-orcid":false,"given":"Johan G.C.","family":"van Hasselt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Burger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Job J.","family":"Engel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeroen J.A.","family":"van Kampen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"McCall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loek","family":"Smits","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hetty","family":"Jolink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leo G.","family":"Visser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"van de Veerdonk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin Ellen","family":"Veldkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chantal P.","family":"Rovers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6649-7190","authenticated-orcid":false,"given":"Rob J.W.","family":"Arts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ebiom.2026.106386_bib1","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1128\/CMR.00062-09","article-title":"A global perspective on hantavirus ecology, epidemiology, and disease","volume":"23","author":"Jonsson","year":"2010","journal-title":"Clin Microbiol Rev"},{"issue":"5","key":"10.1016\/j.ebiom.2026.106386_bib2","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1097\/01.qco.0000244048.38758.1f","article-title":"Diagnosis and treatment of new world hantavirus infections","volume":"19","author":"Mertz","year":"2006","journal-title":"Curr Opin Infect Dis"},{"issue":"10","key":"10.1016\/j.ebiom.2026.106386_bib3","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.3201\/eid2010.140353","article-title":"Person-to-person household and nosocomial transmission of andes hantavirus, Southern Chile, 2011","volume":"20","author":"Martinez-Valdebenito","year":"2014","journal-title":"Emerg Infect Dis"},{"issue":"2","key":"10.1016\/j.ebiom.2026.106386_bib4","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1006\/viro.1997.8976","article-title":"Hantavirus pulmonary syndrome outbreak in Argentina: molecular evidence for person-to-person transmission of Andes virus","volume":"241","author":"Padula","year":"1998","journal-title":"Virology"},{"issue":"23","key":"10.1016\/j.ebiom.2026.106386_bib5","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1056\/NEJMoa2009040","article-title":"\u201cSuper-Spreaders\u201d and person-to-person transmission of Andes virus in Argentina","volume":"383","author":"Martinez","year":"2020","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.ebiom.2026.106386_bib6","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.3201\/eid1208.051127","article-title":"Incubation period of hantavirus cardiopulmonary syndrome","volume":"12","author":"Vial","year":"2006","journal-title":"Emerg Infect Dis"},{"issue":"11","key":"10.1016\/j.ebiom.2026.106386_bib7","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1086\/516786","article-title":"Prospective evaluation of household contacts of persons with hantavirus cardiopulmonary syndrome in Chile","volume":"195","author":"Ferres","year":"2007","journal-title":"J Infect Dis"},{"issue":"Suppl 4","key":"10.1016\/j.ebiom.2026.106386_bib8","doi-asserted-by":"crossref","first-page":"S750","DOI":"10.1093\/clinids\/11.Supplement_4.S750","article-title":"Prospects for treatment of viral hemorrhagic fevers with ribavirin, a broad-spectrum antiviral drug","volume":"11","author":"Huggins","year":"1989","journal-title":"Rev Infect Dis"},{"issue":"9","key":"10.1016\/j.ebiom.2026.106386_bib9","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1086\/425007","article-title":"Placebo-controlled, double-blind trial of intravenous ribavirin for the treatment of hantavirus cardiopulmonary syndrome in North America","volume":"39","author":"Mertz","year":"2004","journal-title":"Clin Infect Dis"},{"issue":"10","key":"10.1016\/j.ebiom.2026.106386_bib10","doi-asserted-by":"crossref","first-page":"4673","DOI":"10.1128\/AAC.00886-13","article-title":"Antiviral efficacy of favipiravir against two prominent etiological agents of Hantavirus pulmonary syndrome","volume":"57","author":"Safronetz","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"10.1016\/j.ebiom.2026.106386_bib11","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0023560","article-title":"In vitro and in vivo activity of ribavirin against Andes virus infection","volume":"6","author":"Safronetz","year":"2011","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.ebiom.2026.106386_bib12","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.3390\/v5112704","article-title":"Ribavirin protects Syrian hamsters against lethal hantavirus pulmonary syndrome--after intranasal exposure to Andes virus","volume":"5","author":"Ogg","year":"2013","journal-title":"Viruses"},{"issue":"3","key":"10.1016\/j.ebiom.2026.106386_bib13","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.antiviral.2012.06.002","article-title":"The Syrian hamster model of Hantavirus pulmonary syndrome","volume":"95","author":"Safronetz","year":"2012","journal-title":"Antiviral Res"},{"issue":"14","key":"10.1016\/j.ebiom.2026.106386_bib14","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1056\/NEJM199404073301401","article-title":"Hantavirus pulmonary syndrome: a clinical description of 17 patients with a newly recognized disease. The Hantavirus Study Group","volume":"330","author":"Duchin","year":"1994","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ebiom.2026.106386_bib15","first-page":"363","article-title":"[Controversies on Hantavirus]","volume":"85","author":"Strella","year":"2025","journal-title":"Medicina (B Aires)"},{"issue":"6","key":"10.1016\/j.ebiom.2026.106386_bib16","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1093\/infdis\/164.6.1119","article-title":"Prospective, double-blind, concurrent, placebo-controlled clinical trial of intravenous ribavirin therapy of hemorrhagic fever with renal syndrome","volume":"164","author":"Huggins","year":"1991","journal-title":"J Infect Dis"},{"issue":"2","key":"10.1016\/j.ebiom.2026.106386_bib17","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.virusres.2004.11.006","article-title":"Metabolism and antiviral activity of ribavirin","volume":"107","author":"Parker","year":"2005","journal-title":"Virus Res"},{"issue":"21","key":"10.1016\/j.ebiom.2026.106386_bib18","doi-asserted-by":"crossref","first-page":"11722","DOI":"10.1128\/JVI.00874-07","article-title":"Ribavirin reveals a lethal threshold of allowable mutation frequency for Hantaan virus","volume":"81","author":"Chung","year":"2007","journal-title":"J Virol"},{"issue":"1","key":"10.1016\/j.ebiom.2026.106386_bib19","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/rmv.483","article-title":"Mechanisms of action of ribavirin against distinct viruses","volume":"16","author":"Graci","year":"2006","journal-title":"Rev Med Virol"},{"issue":"12","key":"10.1016\/j.ebiom.2026.106386_bib20","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1038\/82191","article-title":"The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen","volume":"6","author":"Crotty","year":"2000","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.ebiom.2026.106386_bib21","doi-asserted-by":"crossref","first-page":"575","DOI":"10.3851\/IMP2524","article-title":"Andes-virus-induced cytokine storm is partially suppressed by ribavirin","volume":"18","author":"Khaiboullina","year":"2013","journal-title":"Antivir Ther"},{"issue":"10","key":"10.1016\/j.ebiom.2026.106386_bib25","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1128\/AAC.43.10.2451","article-title":"Pharmacokinetics and absolute bioavailability of ribavirin in healthy volunteers as determined by stable-isotope methodology","volume":"43","author":"Preston","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"10.1016\/j.ebiom.2026.106386_bib27","doi-asserted-by":"crossref","first-page":"515","DOI":"10.3851\/IMP2935","article-title":"The ARRIBA concept: adequate resorption of ribavirin","volume":"20","author":"de Kanter","year":"2015","journal-title":"Antivir Ther"},{"issue":"27","key":"10.1016\/j.ebiom.2026.106386_bib29","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.2174\/092986706778773059","article-title":"Ribavirin-induced anemia: mechanisms, risk factors and related targets for future research","volume":"13","author":"Russmann","year":"2006","journal-title":"Curr Med Chem"},{"issue":"9","key":"10.1016\/j.ebiom.2026.106386_bib30","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1128\/AAC.32.9.1304","article-title":"Ribavirin prophylaxis and therapy for experimental argentine hemorrhagic fever","volume":"32","author":"McKee","year":"1988","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"10.1016\/j.ebiom.2026.106386_bib31","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1086\/657315","article-title":"Review of the literature and proposed guidelines for the use of oral ribavirin as postexposure prophylaxis for Lassa fever","volume":"51","author":"Bausch","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ebiom.2026.106386_bib32","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.antiviral.2017.09.004","article-title":"Cell-line dependent antiviral activity of sofosbuvir against Zika virus","volume":"146","author":"Mumtaz","year":"2017","journal-title":"Antiviral Res"},{"issue":"3","key":"10.1016\/j.ebiom.2026.106386_bib33","doi-asserted-by":"crossref","first-page":"e841","DOI":"10.1093\/cid\/ciac578","article-title":"Pharmacokinetics of ribavirin in the treatment of Lassa fever: an observational clinical Study at the Irrua Specialist teaching Hospital, Edo State, Nigeria","volume":"76","author":"Groger","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.ebiom.2026.106386_bib34","first-page":"158","article-title":"Pharmacokinetics and safety of single-dose ribavirin in patients with chronic renal impairment","volume":"7","author":"Gupta","year":"2013","journal-title":"Drug Discov Ther"},{"issue":"2","key":"10.1016\/j.ebiom.2026.106386_bib35","doi-asserted-by":"crossref","first-page":"89","DOI":"10.5582\/ddt.8.89","article-title":"Exploring the influence of renal dysfunction on the pharmacokinetics of ribavirin after oral and intravenous dosing","volume":"8","author":"K Gupta","year":"2014","journal-title":"Drug Discov Ther"},{"issue":"4","key":"10.1016\/j.ebiom.2026.106386_bib37","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1093\/clind\/24.4.718","article-title":"Treatment of Bolivian hemorrhagic fever with intravenous ribavirin","volume":"24","author":"Kilgore","year":"1997","journal-title":"Clin Infect Dis"},{"issue":"3\u20134","key":"10.1016\/j.ebiom.2026.106386_bib38","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/BF01311063","article-title":"Experimental infection of human vascular endothelial cells by pathogenic and nonpathogenic hantaviruses","volume":"111","author":"Yanagihara","year":"1990","journal-title":"Arch Virol"},{"issue":"8","key":"10.1016\/j.ebiom.2026.106386_bib39","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1038\/sj.bjp.0701775","article-title":"Ribavirin uptake by human erythrocytes and the involvement of nitrobenzylthioinosine-sensitive (es)-nucleoside transporters","volume":"123","author":"Jarvis","year":"1998","journal-title":"Br J Pharmacol"},{"issue":"1","key":"10.1016\/j.ebiom.2026.106386_bib40","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1124\/jpet.108.145854","article-title":"The role of the equilibrative nucleoside transporter 1 (ENT1) in transport and metabolism of ribavirin by human and wild-type or Ent 1-\/- mouse erythrocytes","volume":"329","author":"Endres","year":"2009","journal-title":"J Pharmacol Exp Ther"},{"issue":"5","key":"10.1016\/j.ebiom.2026.106386_bib42","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1093\/infdis\/141.5.580","article-title":"Lassa virus infection of rhesus monkeys: pathogenesis and treatment with ribavirin","volume":"141","author":"Jahrling","year":"1980","journal-title":"J Infect Dis"},{"issue":"2","key":"10.1016\/j.ebiom.2026.106386_bib43","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1128\/iai.44.2.528-533.1984","article-title":"Passive antibody therapy of Lassa fever in cynomolgus monkeys: importance of neutralizing antibody and Lassa virus strain","volume":"44","author":"Jahrling","year":"1984","journal-title":"Infect Immun"},{"issue":"3","key":"10.1016\/j.ebiom.2026.106386_bib44","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1208\/s12248-012-9368-z","article-title":"Population pharmacokinetics and pharmacodynamics of ribavirin in patients with chronic hepatitis C genotype 1 infection","volume":"14","author":"Jin","year":"2012","journal-title":"AAPS J"},{"issue":"4","key":"10.1016\/j.ebiom.2026.106386_bib41","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1128\/AAC.04618-14","article-title":"Population pharmacokinetic modeling of plasma and intracellular ribavirin concentrations in patients with chronic hepatitis C virus infection","volume":"59","author":"Wu","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"10.1016\/j.ebiom.2026.106386_bib45","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1002426","article-title":"Pathogenesis and host response in Syrian hamsters following intranasal infection with Andes virus","volume":"7","author":"Safronetz","year":"2011","journal-title":"PLoS Pathog"},{"issue":"7","key":"10.1016\/j.ebiom.2026.106386_bib46","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/S1473-3099(24)00142-7","article-title":"Viral shedding and viraemia of Andes virus during acute hantavirus infection: a prospective study","volume":"24","author":"Ferres","year":"2024","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"10.1016\/j.ebiom.2026.106386_bib48","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1012875","article-title":"A pan-orthohantavirus human lung xenograft mouse model and its utility for preclinical studies","volume":"21","author":"Rissmann","year":"2025","journal-title":"PLoS Pathog"}],"container-title":["eBioMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396426002707?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396426002707?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T08:15:47Z","timestamp":1786522547000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352396426002707"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":41,"alternative-id":["S2352396426002707"],"URL":"https:\/\/doi.org\/10.1016\/j.ebiom.2026.106386","relation":{},"ISSN":["2352-3964"],"issn-type":[{"value":"2352-3964","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ribavirin post-exposure prophylaxis for Andes virus exposure: a viewpoint","name":"articletitle","label":"Article Title"},{"value":"eBioMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ebiom.2026.106386","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106386"}}